法国药业巨头赛诺菲(SNY.US)盘前跌超4%，报47.23美元。消息面上，赛诺菲公布次季业绩，列账销售99.94亿欧元符合预期，同比增长6%，以固定汇率计升10.1%；撇除单次项目后季度业务经营溢利24.61亿欧元，逊于预期的25.7亿欧元。公司解释，研发成本上升及与合作伙伴再生元制药更高利润分享压抑季度利润。 受集团王牌消炎药Dupixent、疫苗及新疗法需求强劲带动，赛诺菲上调全年销售指引，料销售有高单位数增长，原先料以固定汇率计有中至高单位数增长。赛诺菲确认今年纯利有低双位数增长预测，但指预测已计及新收购业务的所有开支。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.